2023-08-30 Quality Measures Full Member Meeting

Date: August 30th, 2023

Time: 3:30pm ET

Attendees (10)

Action items

•  Anthony DiDonato 9/6 Terminology Meeting - send out Zoom invite
• Anthony DiDonato 9/13 General Meeting - send out Zoom invite
• Dennis Blair Anthony DiDonato 9/13 General Meeting - to confirm clinical data reps can attend (Linda/Yvette etc)
• Stephanie Jones Will send ASCO response to USCDI v4 to Anthony/MITRE - so that MITRE can include in overview spreadsheet

Planned Agenda Topics

1. Review outstanding action items and upcoming timeline from 8/9 and 8/16 QM meetings

   1. "Lela (ASCO) found no concerns regarding a potentially low number of patients for the BRAF measure."

   2. Additional detail: "The ASCO measures team requested feedback on the BRAF Mutational Analysis Results Received for Patients Treated for Metastatic Colorectal Cancer measure using three feedback instruments. An open comment form asked for general impressions of the measure, including the number of potential patients, receiving 11 responses. A feasibility survey assessed data element availability and reporting burden on oncology practices, including denominator counts, and received six responses. None of the open and feasibility survey respondents had concerns regarding a potentially small number of patients meeting the denominator. Finally, we recruited five practices and collected data on 146 patients to test the BRAF measure. All practices comfortably provided 25 asked-for patients for testing, and most offered additional patients. No practices expressed concern that the number of patients meeting the denominator as specified might be too low to report on."
2. Scheduling Updates:
   • QM Terminology meeting: once per month on Wednesdays from 3:30-4:30pm ET – perhaps first Wednesday of each month
     • First call - September 6th - Doug to lead
     • Agenda (1) share template of CDR test scenario(s) - use this call to get a head start and then review materials in October call. Also start with sharing info via email. Sharon to lead walk-through of CDR template (1 scenario example). 
     • Yvette OOO 8/31 - 9/26
     • Stephanie OOO 9/16 - 9/27
   • QM Full Member meeting: once per month on Wednesdays from 3:30-4:30pm ET – perhaps third Wednesday of each month
     • First call - September 13th - Anthony OOO at the HL7 WGM - Doug to lead?
     • Agenda (1) review mCODE/USCDI v4 gap analysis spreadsheet, once available. Anthony confirm with Randi/ASTRO rep will be present. Ask if Ellen Anderson will be available (2) review targeted outreach / any responses? 
   • QM Optional Member meeting: once per month on Wednesdays from 3:30-4:30pm ET – perhaps second Wednesday of each month
     • This call will be tentatively scheduled, and used as needed. Anthony and Doug will manage and cancel when there are no items to discuss outside of the two recurring meetings.
3. HL7 WGM - CodeX QM team (Anthony?) to provide brief ~5 minute project update (high-level) of CodeX QM use case to CQI WG
4. Public Call next steps – follow-up, outreach, etc. 
   1. 2023-08-16 Quality Measures Public Call
5. Standing Item: USCDI v4 has been published & comment period to add new data classes and/or data elements is open until September 20th, 2023 (https://www.healthit.gov/sites/default/files/page/2023-07/Standards_Bulletin_2023-2.pdf)
   1. Update: ASCO quality measures team has reviewed and made suggestions for USCDI v5. Share with other QM members for reference?
   2. Update: MITRE team put together a spreadsheet that documents the gaps between mCODE and USCDI v4 – data elements & data classes that are missing or require additional comment/support are noted. 
6. Conferences:
   
   1. ASCO Quality Care Symposium - abstract accepted as a Poster Presentation!
      1. Next steps to begin preparing poster: https://asco.confex.com/asco/qcs2023/speakercenter.cgi#
   2. poster prep support from Telligen graphics team however ASCO provides helpful templates for poster submissions
7. Backlog item(s):
   1. With the success we've seen so far with RTTD and QM use case collaboration, we may want to consider expanding our approach to genomics-focused measure
      1. Appears to be interest and opportunity to consider ASCO BRAF eCQM for Phase 2+ of QM work
      2. McKesson/Ontada is FHIR-mapping certain genomic concepts, based on data collected from Foundation Medicine. Opportunity to overlap?

      3. Use of genomic data for metastatic colorectal cancer – although there is overlap in assumptions of tumor marker tests, there is some overlap and potential involvement with GenomeX

Discussion Notes

1. Reviewed outstanding action item and upcoming timeline from 8/9 and 8/16 QM meetings

   1. "Lela (ASCO) found no concerns regarding a potentially low number of patients for the BRAF measure."

   2. Additional detail: "The ASCO measures team requested feedback on the BRAF Mutational Analysis Results Received for Patients Treated for Metastatic Colorectal Cancer measure using three feedback instruments. An open comment form asked for general impressions of the measure, including the number of potential patients, receiving 11 responses. A feasibility survey assessed data element availability and reporting burden on oncology practices, including denominator counts, and received six responses. None of the open and feasibility survey respondents had concerns regarding a potentially small number of patients meeting the denominator. Finally, we recruited five practices and collected data on 146 patients to test the BRAF measure. All practices comfortably provided 25 asked-for patients for testing, and most offered additional patients. No practices expressed concern that the number of patients meeting the denominator as specified might be too low to report on."
      
   3. ASCO confirmed that "no concerns" on call today
2. Scheduling Updates:
   • QM Terminology meeting: once per month on Wednesdays from 3:30-4:30pm ET – perhaps first Wednesday of each month
     • First call - September 6th - Anthony PTO / Doug to host via Zoom (Anthony to send Zoom invite)
     • Agenda:
       • Telligen / Sharon will be ready to present example template and information - one scenario 
         • Note:  Will have ASCO reps out (Yvette/Stephanie) out during September 
   • QM Full Member meeting: once per month on Wednesdays from 3:30-4:30pm ET – perhaps third Wednesday of each month
     • First call - September 13th - Anthony OOO at the HL7 WGM - Doug to lead?
     • Agenda:  MITRE doing an analysis of mCode elements needed in USCDI v4
       • Will want to share the analysis regardless - meeting if MITRE rep can walk-through
         
         • Note:  Stephanie out
   • QM Optional Member meeting: once per month on Wednesdays from 3:30-4:30pm ET – perhaps second Wednesday of each month
     • This call will be tentatively scheduled, and used as needed. Anthony and Doug will manage and cancel when there are no items to discuss outside of the two recurring meetings.
3. HL7 WGM - CodeX QM team (Anthony?) to provide brief ~5 minute project update (high-level) of CodeX QM use case to CQI WG
4. Public Call next steps – follow-up, outreach, etc. 
   1. 2023-08-16 Quality Measures Public Call

1. Standing Item: USCDI v4 has been published & comment period to add new data classes and/or data elements is open until September 20th, 2023 (https://www.healthit.gov/sites/default/files/page/2023-07/Standards_Bulletin_2023-2.pdf)
   1. Update: ASCO quality measures team has reviewed and made suggestions for USCDI v5. Share with other QM members for reference?
   2. Update: MITRE team put together a spreadsheet that documents the gaps between mCODE and USCDI v4 – data elements & data classes that are missing or require additional comment/support are noted. 
2. Conferences:
   
   1. ASCO Quality Care Symposium - abstract accepted as a Poster Presentation!
      1. Next steps to begin preparing poster: https://asco.confex.com/asco/qcs2023/speakercenter.cgi#
         1. Anthony will reach out later in September when he is back
         2. ASCO conference organizers provided a template for poster sessions
3. Backlog item(s):
   1. With the success we've seen so far with RTTD and QM use case collaboration, we may want to consider expanding our approach to genomics-focused measure
      1. Appears to be interest and opportunity to consider ASCO BRAF eCQM for Phase 2+ of QM work
      2. McKesson/Ontada is FHIR-mapping certain genomic concepts, based on data collected from Foundation Medicine. Opportunity to overlap?

      3. Use of genomic data for metastatic colorectal cancer – although there is overlap in assumptions of tumor marker tests, there is some overlap and potential involvement with GenomeX